Tier 2 — strong

A randomized trial of Boswellia in association with betaine and myo-inositol in the management of breast fibroadenomas

V Pasta, S Dinicola, A Giuliani, A H Harrath, S H Alwasel, F Tartaglia, A Cucina, M Bizzarri
European review for medical and pharmacological sciences 2016 20(9):1860-1865

Bibliography

PubMed
PMID 27212181
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled trial
ModelHuman participants
Sample64 young women with fibroadenoma
InterventionBoswellia, betaine and myo-inositol plus B vitamins and N-acetylcysteine versus the vitamin/NAC comparison
Duration6 months
EndpointsFibroadenoma volume; Symptoms; Tolerability

What the study showed, in plain terms

Published in 2016, this source examined brain health and combination interventions. Design: Randomized controlled trial. Sample/model: 64 young women with fibroadenoma. The exposure or intervention was Boswellia, betaine and myo-inositol plus B vitamins and N-acetylcysteine versus the vitamin/NAC comparison. Follow-up or treatment period: 6 months.

Fibroadenoma size reduction was greater with the multi-ingredient treatment.

Cannot isolate betaine; small study of benign breast disease, not a trial of cancer prevention.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Fibroadenoma size reduction was greater with the multi-ingredient treatment.
  • The recorded outcome domains were Fibroadenoma volume; Symptoms; Tolerability.
  • The result applies to the tested exposure: Boswellia, betaine and myo-inositol plus B vitamins and N-acetylcysteine versus the vitamin/NAC comparison; 6 months.

What this study can and cannot tell us

  • Cannot isolate betaine; small study of benign breast disease, not a trial of cancer prevention.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Association of choline and betaine levels with cancer incidence and survival: A meta-analysis
Jiyoung Youn et al. · Clinical nutrition (Edinburgh, Scotland) · 2019
Tier 4
Choline and betaine consumption lowers cancer risk: a meta-analysis of epidemiologic studies
Shanwen Sun et al. · Scientific reports · 2016
Tier 4
The association between dietary intakes of methionine, choline and betaine and breast cancer risk: A systematic review and meta-analysis
Heleen Van Puyvelde et al. · Cancer epidemiology · 2023
Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 2
A study of the treatment of Rett syndrome with folate and betaine
Daniel G Glaze et al. · Journal of child neurology · 2009

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology